SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : Penguard Express MIO Comp A

Product code : 3440
Product description : Paint.
Product type : Liquid.

Other means of : Not available.

identification

1.2 Relevant identified uses of the substance or mixture and uses advised against

1.3 Details of the supplier of the safety data sheet

Jotun Boya Sanayi ve Ticaret A.Ş.

Balabandere Caddesi, Hilpark Suites Sitesi No: 10, İstinye 34460 Sarıyer, İstanbul

Tel. +90 212 279 7878 SDSJotun@jotun.com

Başvurulacak Kişi: Deren Ercan deren.metiner@jotun.com

Original preparation date : 14.07.2023

1.4 Emergency telephone number

National Poison Information Center

- +90 224 442 82 93 Uludağ Üniversitesi Zehir Danışma Merkezi (www.uludag.edu.tr/uludag/zehir.html)
- a. ACİL DURUM TELEFONU: Zehirlenme durumlarında gerektiğinde ulusal zehir merkezinin (UZEM) 114 nolu telefonunu arayınız.
- b. ACİL İLK YARDIM MERKEZİ:112

c. İTFAİYE:110

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to regulation SEA: RG.-10/12/2020-31330

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 Aquatic Chronic 3, H412

The weed not in all as if in a large way a constitution

The product is classified as hazardous according to Regulation SEA: RG.-10/12/2020-31330.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms





Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 1/18

SECTION 2: Hazards identification

Signal word : Warning.

Hazard statements : H226 - Flammable liquid and vapour.

H315 - Causes skin irritation.

H317 - May cause an allergic skin reaction. H319 - Causes serious eye irritation.

H412 - Harmful to aquatic life with long lasting effects.

Precautionary statements

General : Not applicable.

Prevention : P280 - Wear protective gloves. Wear eye or face protection.

P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition

sources. No smoking.

P273 - Avoid release to the environment.

P261 - Avoid breathing vapour.

Response : P362 + P364 - Take off contaminated clothing and wash it before reuse.

P302 + P352 - IF ON SKIN: Wash with plenty of water.

P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention. P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes.

Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313 - If eye irritation persists: Get medical advice or attention.

: Not applicable. **Storage**

: P501 - Dispose of contents and container in accordance with all local, regional, **Disposal**

national and international regulations.

: 2,2-bis[4(2,3-epoksipropoksi)fenil]-propan **Hazardous ingredients**

epoxy resin (MW 700-1200)

hydrocarbons, C9-unsaturated, polymerized

Supplemental label

elements

Contains epoxy constituents. May produce an allergic reaction.

Annex 17 - Restrictions on the manufacture, placing on the market and use of

certain dangerous

substances, mixtures and

articles

Special packaging requirements

Containers to be fitted with child-resistant

fastenings

: Not applicable.

: Not applicable.

Tactile warning of danger Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB

: This mixture does not contain any substances that are assessed to be a PBT or a

vPvB.

Other hazards which do not result in classification : None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures Mixture

| Product/ingredient name | Identifiers | % | SEA: RG10/12/2020-31330 | Type |
|---|---------------------------------|-----------|---|---------|
| 2,2-bis[4(2,3-epoksipropoksi) fenil]-propan | EC: 216-823-5 CAS: 1675-54-3 | ≥10 - <25 | Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1B, H317 Aquatic Chronic 2, H411 | [1] |
| xylene | EC: 215-535-7 CAS: 1330-20-7 | ≤10 | Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 | [1] [2] |

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 2/18

SECTION 3: Composition/information on ingredients

| • | | | <u> </u> | |
|--|--|----|--|---------|
| | | | Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 3, H412 | |
| epoxy resin (MW 700-1200) | CAS: 25036-25-3 | ≤5 | Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 | [1] |
| ethylbenzene | EC: 202-849-4 CAS: 100-41-4 Index: 601-023-00-4 | ≤5 | Flam. Liq. 2, H225 Acute Tox. 4, H332 STOT RE 2, H373 (hearing organs) Asp. Tox. 1, H304 Aquatic Chronic 3, H412 | [1] [2] |
| benzyl alcohol | EC: 202-859-9 CAS: 100-51-6 Index: 603-057-00-5 | ≤3 | Acute Tox. 4, H302 Acute Tox. 4, H332 Eye Irrit. 2, H319 | [1] |
| 1-methoxypropan-2-ol | EC: 203-539-1 CAS: 107-98-2 | ≤3 | Flam. Liq. 3, H226 STOT SE 3, H336 | [1] [2] |
| hydrocarbons, C9-unsaturated, polymerized | CAS: 71302-83-5 | ≤3 | Skin Sens. 1, H317 Aquatic Chronic 3, H412 | [1] |
| | | | See Section 16 for the full text of the H statements declared above. | |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs or vPvBs or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.

Inhalation

: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Skin contact

: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Ingestion

: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 3/18

SECTION 4: First aid measures

as a collar, tie, belt or waistband.

Protection of first-aiders

: No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effects

Eye contact : Causes serious eye irritation.

Inhalation : No known significant effects or critical hazards.

Skin contact: Causes skin irritation. May cause an allergic skin reaction.

Ingestion : No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact: Adverse symptoms may include the following:

pain or irritation watering redness

Inhalation : No specific data.

Skin contact: Adverse symptoms may include the following:

irritation redness

Ingestion : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : Treat symptomatically. Contact poison treatment specialist immediately if large

quantities have been ingested or inhaled.

Specific treatments: No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing

media

: Use dry chemical, CO2, water spray (fog) or foam.

Unsuitable extinguishing

media

: Do not use water jet.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture

: Flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

Hazardous thermal decomposition products

: Decomposition products may include the following materials:

carbon dioxide carbon monoxide metal oxide/oxides

5.3 Advice for firefighters

Special protective actions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 4/18

SECTION 5: Firefighting measures

Special protective equipment for fire-fighters

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders

If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

6.3 Methods and material for containment and cleaning up

Small spill

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.

6.4 Reference to other sections

See Section 1 for emergency contact information.
 See Section 8 for information on appropriate personal protective equipment.
 See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures

: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 5/18

SECTION 7: Handling and storage

Advice on general occupational hygiene

: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

See Technical Data Sheet / packaging for further information.

Regulation on the prevention of major industrial accidents and reduction of their effects - Reporting thresholds

Danger criteria

| | Notification and MAPP threshold | Safety report threshold |
|-----|---------------------------------|-------------------------|
| P5c | 5000 tonne | 50000 tonne |

7.3 Specific end use(s)

Recommendations : Not available.

Industrial sector specific : Not available.

solutions

SECTION 8: Exposure controls/personal protection 8.1 Control parameters

Occupational exposure limits

| Product/ingredient name | Exposure limit values |
|-------------------------|---|
| x ýlene | TR ISGGM OEL (Turkey, 12/2013). [Xylene (pure and mixed isomers)] Absorbed through skin. TWA: 221 mg/m³ 8 hours. TWA: 50 ppm 8 hours. STEL: 442 mg/m³ 15 minutes. STEL: 100 ppm 15 minutes. |
| ethylbenzene | TR ISGGM OEL (Turkey, 12/2013). Absorbed through skin. TWA: 442 mg/m³ 8 hours. TWA: 100 ppm 8 hours. STEL: 884 mg/m³ 15 minutes. STEL: 200 ppm 15 minutes. |
| 1-methoxypropan-2-ol | TR ISGGM OEL (Turkey, 12/2013). Absorbed through skin. TWA: 375 mg/m³ 8 hours. TWA: 100 ppm 8 hours. STEL: 568 mg/m³ 15 minutes. STEL: 150 ppm 15 minutes. |

Biological exposure indices

No exposure indices known.

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 6/18

SECTION 8: Exposure controls/personal protection

procedures

Recommended monitoring: Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

| DNEL Long term Dornal DNEL Long term Dornal DNEL Long term Dornal DNEL Long term Dornal DNEL Long term Dornal Inhalation DNEL Long term Dornal Inhalation DNEL Long term Dornal Long term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | Product/ingredient name | Type | Exposure | Value | Population | Effects |
|--|--------------------------------------|---------|------------------|------------------------|-------------------|------------|
| DNEL Long term Oral D.5 mg/kg Dw/day Dopulation Dwell Long term Dopulation Dwell Dwe | 2,2-bis[4(2,3-epoksipropoksi)fenil]- | DNEL | Long term Dermal | | | Systemic |
| DNEL Long term Dermal Inhalation DNEL Long term General population Workers Systemic Morkers Systemic Morkers Systemic Morkers Systemic Inhalation DNEL Long term General population Workers Systemic Inhalation DNEL Long term General population DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Cong term Oral DNEL Long term Oral DNEL Cong term Dermal DNEL Cong term Dermal DNEL Cong term Dermal DNEL Cong term Dermal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Cong term Dermal DNEL DNEL Dneg term Dermal DNEL Dneg term Dermal DNEL Dneg term Dermal DNEL Dneg term Dermal DNEL | propan | | | bw/day | | |
| DNEL Long term Dermal D.75 mg/s kg bw/day D.82 Long term D.82 Long term D.82 Long term D.82 Long term D.82 Long term D.83 D.84 D.84 D.85 D.84 D.85 D.84 D.85 | | DNEL | Long term Oral | | General | Systemic |
| DNEL Long term Inhalation DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Long term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Short term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Cong term (habalation) DNEL Short term (habalation) DNEL Cong term | | | | bw/day | population | |
| DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral Inhalation DNEL Long term Oral Inhalation DNEL Long term Oral Inhalation DNEL Long term Dermal Inhalation DNEL DNEL Long term Dermal Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | DNEL | Long term Dermal | 0.75 mg/ | Workers | Systemic |
| DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral Inhalation DNEL Long term Oral Inhalation DNEL Long term Oral Inhalation DNEL Long term Dermal Inhalation DNEL DNEL Long term Dermal Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | | kg bw/day | | |
| Inhalation Long term Lon | | DNEL | Long term | 0.87 mg/m ³ | General | Systemic |
| DNEL Long term | | | Inhalation | | | • |
| Inhalation | | DNEL | Long term | 4.93 mg/m ³ | | Systemic |
| DNEL | | | | J | | |
| DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Domester Domes | xvlene | DNEL | | 12.5 mg/ | General | Systemic |
| DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Dong term Dermal DNEL Dong term Dermal DNEL Dong term Dermal DNEL Dong term Dermal DNEL Dong term Dermal DNEL Long term Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral DNEL Dral | , | | | | | , |
| Inhalation DNEL Long term Dremal Long term Dremal Long term Dremal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dremal DNEL Long term Dremal DNEL Dremal DNEL Dremal DNEL Dremal DNEL Dremal DNEL Dremal DNEL Dremal DNEL Dremal Dnel Dremal DNEL Dremal Dre | | DNEL | Long term | | | Local |
| DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Inhalation DNEL Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation | | | | | | |
| Inhalation Long term Dermal DNEL Long term Dermal Long term Dermal Dwiday Dwell Long term Dermal Dwell Long term Dermal Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Dwell Dwell Dwell Dwell Long term Dwell Dwell Dwell Dwell Dwell Long term Dwell Dwell Dwell Dwell Long term Dwell Dwell Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Long term Dwell Dwel | | DNEI | | 65.3 mg/m ³ | | Systemic |
| DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | DIVLE | | oo.o mg/m | | Cyclonno |
| DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Tomal DNEL Long term Tomal DNEL Long term DNEL Short term DNEL Long t | | DNEI | | 125 ma/ka | | Systemic |
| DNEL Long term Dermal linhalation DNEL Short term Inhalation DNEL Cong term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Drail DNEL Long term | | DIVLL | Long term Demia | | | Systernic |
| DNEL Long term Inhalation DNEL Long term 221 mg/m³ Workers Systemic Inhalation DNEL Short term 260 mg/m³ General population DNEL Short term 16 mlalation DNEL Short term 16 mlalation DNEL Short term 16 mlalation DNEL Short term 16 mlalation DNEL Short term 16 mlalation DNEL Short term 16 mlalation DNEL Short term 16 mlalation DNEL Short term 16 mlalation DNEL Short term 17 mlalation DNEL Long term 18 mlalation DNEL Long term 18 mlalation DNEL Long term 16 mlalation DNEL Long term 17 mg/m³ Workers DNEL Long term 18 mg/kg DNEL Long term 180 mg/kg DNEL Long term 180 mg/kg DNEL Long term 180 mg/kg DNEL Short term 293 mg/m³ Workers DNEL Long term 180 mg/kg DNEL Short term 293 mg/m³ Workers DNEL Long term 180 mg/kg DNEL Short term 293 mg/m³ Workers DNEL Short term 260 mg/m³ Workers DNEL Short term 260 mg/m³ Workers DNEL Short term 260 mg/m³ Workers DNEL Short term 260 mg/m³ Workers DNEL Short term 260 mg/m³ Workers DNEL Short term 260 mg/m³ Workers DNEL Short term 260 mg/m³ Workers DNEL Short term 260 mg/m³ Workers DN | | DVIEL | Long torm Dormal | | | Systemis |
| DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Oral Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral Long term DNEL Long ter | | DINEL | Long term Demia | | WOIKEIS | Systernic |
| Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DMEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal | | DNE | Law er ta was | | \\/ a w c a wa | Lagal |
| DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DMEL Long term Inhalation DMEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral ONEL Long term Oral Systemic DNEL Short term DNEL Long term Oral DNEL Long term Oral ONEL Short term ONEL DNEL Long term Oral ONEL Short term ONEL DNEL Long term Oral ONEL Short term ONEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL D | | DINEL | | 221 mg/m ² | vvorkers | Locai |
| Inhalation Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DMEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | האודו | | 004/3 | \^/ | 0 |
| DNEL Short term Inhalation Short term Inhalation Short term Inhalation Short term Inhalation Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation Inhalation DMEL Short term Inhalation DMEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral Short term Inhalation DNEL Long term Oral Short term Inhalation DNEL Long term Oral Short term Inhalation DNEL Long term Oral Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal Short term Inhalation DNEL Long term Dermal Short term Inhalation DNEL Long term Dermal Short term Systemic Systemic Short term Sho | | DNEL | | 221 mg/m ³ | vvorkers | Systemic |
| Inhalation Short term 260 mg/m³ General population General population General population Workers Local Inhalation Short term 1halation Short term Inhalation DNEL Short term 1halation DNEL Short term 1halation DMEL Short term 1halation DNEL Short term 1halation DNEL Long term 0ral DNEL Long term 15 mg/m³ General population Workers Systemic Morkers Systemic DNEL Long term 15 mg/m³ General population General population General population General population General population General population Morkers Systemic DNEL Long term 15 mg/m³ General population Workers Systemic DNEL Long term 77 mg/m³ Workers Systemic DNEL Long term 180 mg/kg bw/day DNEL Short term 293 mg/m³ Workers Systemic DNEL Short term 293 mg/m³ Workers Systemic DNEL Long term Oral Short term 293 mg/m³ Workers Systemic DNEL Long term Oral Short term 293 mg/m³ Workers Systemic DNEL Long term Oral Short term 293 mg/m³ DNEL Long term Oral Short term 293 mg/m³ DNEL Long term Dral Short term 293 mg/m³ General Systemic DNEL Long term Dral Short term 293 mg/m³ General Systemic DNEL Long term Dral Short term Systemic Systemic DNEL Long term Dral Short term Systemic Sy | | - N. I. | | | | |
| DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DMEL Short term Inhalation DMEL Short term Inhalation DMEL Long term Oral DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Oral DNEL Long term Dermal DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Oral DNEL Long term Dermal DNEL Long | | DNEL | | 260 mg/m ³ | | Local |
| Inhalation Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DMEL Short term Inhalation DMEL Short term Inhalation DMEL Short term Inhalation DMEL Short term Inhalation DNEL Long term Oral Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal | | | | | | |
| DNEL Short term Inhalation Short term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Oral DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Dermal DNEL Cong term Inhalation DNEL Cong term Dermal DNEL Cong term Dermal DNEL Cong term DNEL C | | DNEL | | 260 mg/m ³ | | Systemic |
| Inhalation Short term 1442 mg/m³ Workers Systemic | | | | | | |
| ethylbenzene DNEL Short term Inhalation Long term Long term Inhalation DMEL Short term Inhalation DMEL Short term Inhalation DNEL Long term Oral Long term Oral DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL Systemic DNEL DNEL Long term Dermal DNEL DNEL DNEL Long term Dermal DNEL Systemic DNEL DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | DNEL | | 442 mg/m ³ | Workers | Local |
| ethylbenzene DMEL Long term Long te | | | | | | |
| ethylbenzene DMEL Long term Inhalation DMEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dormal DNEL Long term Dermal DNEL | | DNEL | Short term | 442 mg/m ³ | Workers | Systemic |
| Inhalation DMEL Short term Inhalation DNEL Long term Oral 1.6 mg/kg bw/day population DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal 180 mg/kg bw/day DNEL Short term Pormal Inhalation DNEL Short term Pormal Inhalation DNEL Long term Oral 4 mg/kg General population DNEL Short term Pormal Pormal Systemic DNEL Long term Oral 4 mg/kg General population DNEL Long term Oral 5 mg/m³ Workers Systemic DNEL Short term Pormal Pormal Population Population Population Systemic DNEL Long term Dermal Population Systemic | | | Inhalation | | | |
| DMEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term 293 mg/m³ Workers DNEL Long term Oral DNEL Long term Oral DNEL Long term Derma | ethylbenzene | DMEL | Long term | 442 mg/m ³ | Workers | Local |
| Inhalation DNEL Long term Oral DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Short term (Inhalation) DNEL Short term (Inhalation) DNEL Short term (Inhalation) DNEL Long term Oral (Inhalation) DNEL Long | | | Inhalation | | | |
| Inhalation DNEL Long term Oral DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Long term (Inhalation) DNEL Short term (Inhalation) DNEL Short term (Inhalation) DNEL Short term (Inhalation) DNEL Long term Oral (Inhalation) DNEL Long | | DMEL | Short term | 884 mg/m ³ | Workers | Systemic |
| DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Systemic DNEL Long term Dermal DNEL Systemic Systemic DNEL Long term Dermal DNEL Systemic Systemic Systemic DNEL Systemic DNEL Systemic DNEL Systemic Systemic Systemic Systemic Systemic Systemic DNEL Systemic DNEL Systemic Systemic Systemic Systemic Systemic Systemic Systemic DNEL Systemic System | | | | | | |
| DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Systemic DNEL Long term Dermal DNEL Systemic Systemic DNEL Long term Dermal DNEL Systemic Systemic Systemic DNEL Systemic DNEL Systemic DNEL Systemic Systemic Systemic Systemic Systemic Systemic DNEL Systemic DNEL Systemic Systemic Systemic Systemic Systemic Systemic Systemic DNEL Systemic System | | DNEL | Long term Oral | 1.6 mg/kg | General | Systemic |
| DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Long term Dermal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral 4 mg/kg General population Workers Systemic Workers Systemic Workers Systemic Workers Systemic Systemic DNEL Long term Oral 4 mg/kg General population DNEL Long term Dermal 4 mg/kg General Systemic | | | | | population | |
| Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Systemic Systemic Systemic Systemic Systemic Systemic Systemic Systemic Systemic Systemic Systemic | | DNEL | Long term | | | Systemic |
| DNEL Long term 77 mg/m³ Workers Systemic | | | | | | - , |
| Inhalation DNEL Long term Dermal 180 mg/kg bw/day DNEL Short term 293 mg/m³ Workers Local benzyl alcohol DNEL Long term Oral 4 mg/kg General population DNEL Long term Dermal 4 mg/kg General Systemic | | DNFI | | 77 mg/m³ | | Systemic |
| DNEL Long term Dermal 180 mg/kg bw/day DNEL Short term 293 mg/m³ Workers Local benzyl alcohol DNEL Long term Oral 4 mg/kg General population DNEL Long term Dermal 4 mg/kg General Systemic | | 01122 | • | g, | TT GIRGIG | Gyotonno |
| benzyl alcohol DNEL Short term | | DNEI | | 180 ma/ka | Workers | Systemic |
| benzyl alcohol DNEL Short term 293 mg/m³ Workers Local | | D. 1CL | Long tomi Domial | | TTOINGIO | Cyolonno |
| benzyl alcohol DNEL Inhalation Long term Oral 4 mg/kg General Systemic bw/day population DNEL Long term Dermal 4 mg/kg General Systemic Systemic Systemic Company C | | DNE | Short term | | Workers | Local |
| benzyl alcohol DNEL Long term Oral 4 mg/kg bw/day population DNEL Long term Dermal 4 mg/kg General population DNEL Long term Dermal 4 mg/kg General Systemic | | DIVLE | | 200 mg/m | W OINGIO | Local |
| DNEL Long term Dermal bw/day population Systemic | honzyl alcohol | חאבו | | 4 ma/ka | Conoral | Systemis |
| DNEL Long term Dermal 4 mg/kg General Systemic | репzугаюног | DIVEL | Long term Oral | | | Systemic |
| | | ראורי | Lamarte | , | | Cuete:-: |
| I hwidov I nonviotion | | DNEL | Long term Dermal | | | Systemic |
| | | D | 1 | bw/day | population | 0 |
| DNEL Long term 5.4 mg/m³ General Systemic | | DNEL | Long term | 5.4 mg/m ³ | General | Systemic |

Date of revision 7/18 : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01

SECTION 8: Exposure controls/personal protection

| | | | 1 | | 1 |
|---|------|--------------------------|-----------------------|--------------------|----------|
| | | Inhalation | | population | |
| | DNEL | Long term Dermal | 8 mg/kg bw/day | Workers | Systemic |
| | DNEL | Short term Oral | 20 mg/kg | General | Systemic |
| | | | bw/day | population | , |
| | DNEL | Short term Dermal | 20 mg/kg | General | Systemic |
| | | | bw/day | population | |
| | DNEL | Long term Inhalation | 22 mg/m³ | Workers | Systemic |
| | DNEL | Short term Inhalation | 27 mg/m ³ | General population | Systemic |
| | DNEL | Short term Dermal | 40 mg/kg bw/day | Workers | Systemic |
| | DNEL | Short term Inhalation | 110 mg/m³ | Workers | Systemic |
| 1-methoxypropan-2-ol | DNEL | Long term Oral | 33 mg/kg bw/day | General population | Systemic |
| | DNEL | Long term Inhalation | 43.9 mg/m³ | | Systemic |
| | DNEL | Long term Dermal | 78 mg/kg bw/day | General population | Systemic |
| | DNEL | Long term Dermal | 183 mg/kg bw/day | Workers | Systemic |
| | DNEL | Long term Inhalation | 369 mg/m ³ | Workers | Systemic |
| | DNEL | Short term Inhalation | 553.5 mg/ m³ | Workers | Local |
| | DNEL | Short term Inhalation | 553.5 mg/ m³ | Workers | Systemic |
| hydrocarbons, C9-unsaturated, polymerized | DNEL | Long term Dermal | 3.5 mg/kg bw/day | Workers | Systemic |
| | DNEL | Long term Inhalation | 1.41 mg/m³ | Workers | Systemic |

PNECs

| Product/ingredient name | Compartment Detail | Value | Method Detail |
|--|---------------------------|-----------------|----------------------|
| 2,2-bis[4(2,3-epoksipropoksi)fenil]-propan | Fresh water | 0.006 mg/l | - |
| | Marine | 0.0006 mg/l | - |
| | Sewage Treatment Plant | 10 mg/l | - |
| | Fresh water sediment | 0.996 mg/l | - |
| | Marine water sediment | 0.0996 mg/l | - |
| | Soil | 0.196 mg/l | - |
| ylene | Fresh water | 0.327 mg/l | - |
| , | Marine | 0.327 mg/l | - |
| | Sewage Treatment Plant | 6.58 mg/l | - |
| | Fresh water sediment | 12.46 mg/kg dwt | - |
| | Marine water sediment | 12.46 mg/kg dwt | _ |
| | Soil | 2.31 mg/kg dwt | - |
| thylbenzene | Fresh water | 0.1 mg/l | - |
| • | Marine | 0.01 mg/l | - |
| | Sewage Treatment Plant | 9.6 mg/l | - |
| | Fresh water sediment | 13.7 mg/kg dwt | - |
| | Soil | 2.68 mg/kg dwt | - |
| | Secondary Poisoning | 20 mg/kg | - |
| enzyl alcohol | Fresh water | 1 mg/l | - |
| • | Marine | 0.1 mg/l | - |
| | Sewage Treatment Plant | 39 mg/l | - |
| | Fresh water sediment | 5.27 mg/kg dwt | - |
| | Marine water sediment | 0.527 mg/kg dwt | - |
| | Soil | 0.456 mg/kg dwt | _ |

Date of revision: 29.11.2023Original preparation date: 14.07.2023Version: 1.018/18

SECTION 8: Exposure controls/personal protection

| 1-methoxypropan-2-ol | Fresh water | 10 mg/l | - |
|---|-----------------------|-----------------|---|
| | Marine | 1 mg/l | - |
| | Sewage Treatment | 100 mg/l | - |
| | Plant | | |
| | Fresh water sediment | 52.3 mg/kg dwt | - |
| | Marine water sediment | 5.2 mg/kg dwt | - |
| | Soil | 5.49 mg/kg dwt | - |
| hydrocarbons, C9-unsaturated, polymerized | Fresh water | 54 µg/l | - |
| | Marine | 5.4 µg/l | - |
| | Sewage Treatment | 2.2 mg/l | - |
| | Plant | | |
| | Fresh water sediment | 1584 mg/kg dwt | - |
| | Marine water sediment | 158 mg/kg dwt | - |
| | Soil | 316.7 mg/kg dwt | - |
| | Secondary Poisoning | 200 mg/kg | - |
| | | | |

8.2 Exposure controls

Appropriate engineering controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying to ISO 16321-1:2022 should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.

Skin protection Hand protection

: There is no one glove material or combination of materials that will give unlimited resistance to any individual or combination of chemicals.

The breakthrough time must be greater than the end use time of the product. The instructions and information provided by the glove manufacturer on use, storage, maintenance and replacement must be followed.

Gloves should be replaced regularly and if there is any sign of damage to the glove material.

Always ensure that gloves are free from defects and that they are stored and used correctly.

The performance or effectiveness of the glove may be reduced by physical/chemical damage and poor maintenance.

Barrier creams may help to protect the exposed areas of the skin but should not be applied once exposure has occurred.

Wear suitable gloves tested to ISO 374-1:2016.

May be used, gloves(breakthrough time) 4 - 8 hours: neoprene (> 0.35 mm), butyl rubber (> 0.4 mm), PVC (> 0.5 mm)

Recommended, gloves(breakthrough time) > 8 hours: Viton® (> 0.7 mm), nitrile rubber (> 0.75 mm), 4H/Silver Shield® (> 0.07 mm), Teflon (> 0.35 mm), polyvinyl alcohol (PVA) (> 0.3 mm)

For right choice of glove materials, with focus on chemical resistance and time of penetration, seek advice by the supplier of chemical resistant gloves.

The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 9/18

SECTION 8: Exposure controls/personal protection

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Environmental exposure controls

Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

: Lowest known value: 120.17°C (248.3°F) (1-methoxy-2-propanol). Weighted

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance

Physical state : Liquid. Colour : Grey, Red Odour : Characteristic. **Odour threshold** : Not applicable. Melting point/freezing point : Not applicable.

Initial boiling point and

boiling range

average: 214.79°C (418.6°F) : Not applicable.

Flammability (solid, gas) Upper/lower flammability or

explosive limits

: 0.8 - 13.74%

Flash point : Closed cup: 32°C (89.6°F)

Auto-ignition temperature : Lowest known value: 270°C (518°F) (1-methoxy-2-propanol).

Decomposition temperature Not available. pН : Not applicable.

Viscosity Kinematic (40°C): >20.5 mm²/s

Solubility(ies)

| Media | Result |
|-------------------------|----------------------------|
| cold water hot water | Not soluble Not soluble |

Partition coefficient: n-octanol/: Not available.

water

: Highest known value: 1.2 kPa (9.3 mm Hg) (at 20°C) (ethylbenzene). Weighted Vapour pressure

average: 0.43 kPa (3.23 mm Hg) (at 20°C)

Highest known value: 0.84 (ethylbenzene) Weighted average: 0.67compared

with butyl acetate

: 1.649 to 1.702 g/cm³ **Density**

Highest known value: 11.7 (Air = 1) (epoxy resin (MW ≤ 700)). Weighted Vapour density

average: 7.43 (Air = 1)

Explosive properties : Not available. **Oxidising properties** : Not available.

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 10/18

SECTION 9: Physical and chemical properties

Particle characteristics

Median particle size : Not applicable.

9.2 Other information

No additional information.

SECTION 10: Stability and reactivity

10.1 Reactivity

: No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability

10.3 Possibility of

: The product is stable.

hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid

: Avoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld,

braze, solder, drill, grind or expose containers to heat or sources of ignition.

10.5 Incompatible materials

: Reactive or incompatible with the following materials:

oxidising materials

10.6 Hazardous decomposition products

: Under normal conditions of storage and use, hazardous decomposition products

should not be produced.

Shelf life at 23 °C : 24 month(s)

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

| Product/ingredient name | Result | Species | Dose | Exposure |
|-----------------------------|------------------------|------------|-------------|----------|
| 2,2-bis[4 | LD50 Dermal | Rabbit | 20 g/kg | - |
| (2,3-epoksipropoksi)fenil]- | | | | |
| propan | | | | |
| | LD50 Oral | Mouse | 15600 mg/kg | - |
| xylene | LC50 Inhalation Vapour | Rat | 20 mg/l | 4 hours |
| | LD50 Oral | Rat | 4300 mg/kg | - |
| | TDLo Dermal | Rabbit | 4300 mg/kg | - |
| ethylbenzene | LC50 Inhalation Vapour | Rat - Male | 17.8 mg/l | 4 hours |
| | LD50 Dermal | Rabbit | >5000 mg/kg | - |
| | LD50 Oral | Rat | 3500 mg/kg | - |
| benzyl alcohol | LD50 Oral | Rat | 1230 mg/kg | - |
| 1-methoxypropan-2-ol | LD50 Dermal | Rabbit | 13 g/kg | - |
| | LD50 Oral | Rat | 6600 mg/kg | - |
| hydrocarbons, | LD50 Dermal | Rat | 2000 mg/kg | - |
| C9-unsaturated, | | | | |
| polymerized | | | | |
| | LD50 Oral | Rat | 2000 mg/kg | - |

Conclusion/Summary

: Not available.

Acute toxicity estimates

| Product/ingredient name | Oral (mg/ kg) | Dermal (mg/kg) | Inhalation (gases) (ppm) | Inhalation (vapours) (mg/l) | Inhalation (dusts and mists) (mg/l) |
|-----------------------------|------------------|-------------------|--------------------------------|-----------------------------------|--|
| Fenguard Express MIO Comp A | 48368.1 | 11922.9 | N/A | 157.7 | 59.0 |
| xylene | 4300 | 1100 | N/A | 20 | N/A |
| ethylbenzene | 3500 | N/A | N/A | 17.8 | N/A |
| benzyl alcohol | 1230 | N/A | N/A | N/A | 1.5 |
| 1-methoxy-2-propanol | 6600 | 13000 | N/A | N/A | N/A |

Irritation/Corrosion

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 11/18

SECTION 11: Toxicological information

| Product/ingredient name | Result | Species | Score | Exposure | Observation |
|---|------------------------|------------------------------------|-------|--------------------------|-------------|
| 2,2-bis[4(2,3-epoksipropoksi) fenil]-propan | Eyes - Severe irritant | Rabbit | - | 24 hours 2 milligrams | - |
| | Skin - Mild irritant | Rabbit | - | 500 milligrams | - |
| xylene | Eyes - Mild irritant | Rabbit | - | 87 milligrams | - |
| | Skin - Mild irritant | Rat | - | 8 hours 60 microliters | - |
| epoxy resin (MW 700-1200) | Eyes - Mild irritant | Mammal - species unspecified | - | - | - |
| | Skin - Mild irritant | Mammal - species unspecified | - | - | - |
| benzyl alcohol | Eyes - Mild irritant | Mammal - species unspecified | - | - | - |
| 1-methoxypropan-2-ol | Eyes - Mild irritant | Rabbit | - | 24 hours 500 mg | - |
| | Skin - Mild irritant | Rabbit | - | 500 mg | - |

Conclusion/Summary

: Not available.

Sensitisation

| Product/ingredient name | Route of exposure | Species | Result |
|--|-------------------|------------------------------|-------------|
| 2,2-bis[4(2,3-epoksipropoksi) fenil]-propan | skin | Mammal - species unspecified | Sensitising |
| epoxy resin (MW 700-1200) | skin | Mammal - species unspecified | Sensitising |
| hydrocarbons, C9-unsaturated, polymerized | skin | Mouse | Sensitising |

Conclusion/Summary

: Not available.

Mutagenicity

Conclusion/Summary: Not available.

Carcinogenicity

Conclusion/Summary: Not available.

Reproductive toxicity

Conclusion/Summary: Not available.

Teratogenicity

Conclusion/Summary: Not available.

Specific target organ toxicity (single exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|-------------------------|------------|-------------------|------------------------------|
| xylene | Category 3 | - | Respiratory tract irritation |
| 1-methoxypropan-2-ol | Category 3 | - | Narcotic effects |

Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|-------------------------|------------|-------------------|----------------|
| ethylbenzene | Category 2 | - | hearing organs |

Aspiration hazard

| Product/ingredient name | Result | |
|-------------------------|---|--|
| xylene ethylbenzene | ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 | |

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 12/18

SECTION 11: Toxicological information

Information on likely routes : Not available.

of exposure

Potential acute health effects

Eye contact : Causes serious eye irritation.

Inhalation : No known significant effects or critical hazards.

Skin contact: Causes skin irritation. May cause an allergic skin reaction.

Ingestion : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact: Adverse symptoms may include the following:

pain or irritation watering redness

Inhalation : No specific data.

Skin contact: Adverse symptoms may include the following:

irritation redness

Ingestion : No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

Potential immediate : No

effects

: Not available.

Potential delayed effects : Not available.

Long term exposure

Potential immediate

effects

: Not available.

Potential delayed effects : Not available.

Potential chronic health effects

Not available.

Conclusion/Summary: Not available.

General : Once sensitized, a severe allergic reaction may occur when subsequently exposed

to very low levels.

Carcinogenicity : No known significant effects or critical hazards.
 Mutagenicity : No known significant effects or critical hazards.
 Reproductive toxicity : No known significant effects or critical hazards.

Other information : Not available.

SECTION 12: Ecological information

12.1 Toxicity

| Product/ingredient name | Result | Species | Exposure |
|---|-----------------------------------|----------------------------------|----------|
| 2,2-bis[4(2,3-epoksipropoksi) fenil]-propan | Acute EC50 1.4 mg/l | Daphnia | 48 hours |
| | Acute LC50 3.1 mg/l | Fish - pimephales promelas | 96 hours |
| | Chronic NOEC 0.3 mg/l | Fish | 21 days |
| xylene | Acute LC50 8500 μg/l Marine water | Crustaceans - Palaemonetes pugio | 48 hours |
| | Acute LC50 13400 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| ethylbenzene | Acute EC50 7700 µg/l Marine water | Algae - Skeletonema costatum | 96 hours |
| - | Acute EC50 2.93 mg/l | Daphnia | 48 hours |
| | Acute LC50 4.2 mg/l | Fish | 96 hours |

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 13/18

Conforms to regulation No. 30105, Turkey KKDIK, Annex 2

Penguard Express MIO Comp A

SECTION 12: Ecological information

Conclusion/Summary

: This material is harmful to aquatic life with long lasting effects.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

| Aquatic half-life | Photolysis | Biodegradability |
|-------------------|------------|--------------------|
| - | - | Not readily |
| - | - | Readily |
| - | | Readily Readily |
| | • | - |

12.3 Bioaccumulative potential

| Product/ingredient name | LogPow | BCF | Potential |
|---|----------------------------|-------------------------------|--------------------------|
| 2,2-bis[4(2,3-epoksipropoksi) fenil]-propan | 2.64 to 3.78 | 31 | low |
| xylene ethylbenzene benzyl alcohol 1-methoxypropan-2-ol hydrocarbons, C9-unsaturated, polymerized | 3.6 0.87 <1 3.627 | 8.1 to 25.9 - <100 - | low low low low |

12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility : Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects: No known significant effects or critical hazards.

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

Product

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste

Waste list

: Yes.

| Waste code | Waste code definition |
|------------|---|
| 08 01 11* | Waste paint and varnish containing organic solvents or other dangerous substances |

Packaging

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 14/18

SECTION 13: Disposal considerations

Special precautions

This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

| | ADR/RID | ADN | IMDG | IATA |
|----------------------------------|---------|--------|--------|--------|
| 14.1 UN number | UN1263 | UN1263 | UN1263 | UN1263 |
| 14.2 UN proper shipping name | Paint | Paint | Paint | Paint |
| 14.3 Transport hazard class(es) | 3 | 3 | 3 | 3 |
| 14.4 Packing group | III | III | III | III |
| 14.5 Environmental hazards | No. | Yes. | No. | No. |

Additional information

ADR/RID

: Hazard identification number 30

Tunnel code (D/E)

ADR/RID: Viscous substance. Not goods of class 3, ref. 2.2.3.1.5 (only applicable to receptacles < 450 litre capacity).

ADN

The product is only regulated as an environmentally hazardous substance when transported in tank vessels.

: Emergency schedules F-E, S-E

IMDG

MDG: Viscous substance. Transport in accordance with 2.3.2.5 of the IMDG

Code (only applicable to receptacles < 450 litre capacity).

user

14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in

the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

: Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture **Turkey Regulation No. 30105, KKDIK**

Annex 14 - List of substances subject to authorization

Annex 14

None of the components are listed.

Substances of very high concern

None of the components are listed.

Date of revision : 29.11.2023 : 14.07.2023 Version : 1.01 15/18 Original preparation date

: Not applicable.

Penguard Express MIO Comp A

SECTION 15: Regulatory information

Annex 17 - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Ozone depleting substances

Not listed.

Regulation on the prevention of major industrial accidents and reduction of their effects

This product is controlled under the Regulation on the prevention of major industrial accidents and reduction of their effects.

Danger criteria

Category

P5c

EU regulations

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions : Not applicable. on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Persistent Organic Pollutants

Not listed.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

15.2 Chemical safety assessment

: This product contains substances for which Chemical Safety Assessments are still required.

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 16/18

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and

: ATE = Acute Toxicity Estimate

acronyms

EUH statement = SÉA-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to regulation SEA: RG.-10/12/2020-31330

| Classification | Justification |
|-------------------------|-----------------------|
| Flam. Liq. 3, H226 | On basis of test data |
| Skin Irrit. 2, H315 | Calculation method |
| Eye Irrit. 2, H319 | Calculation method |
| Skin Sens. 1, H317 | Calculation method |
| Aquatic Chronic 3, H412 | Calculation method |

Full text of abbreviated H statements

| H225 | Highly flammable liquid and vapour. |
|------|--|
| H226 | Flammable liquid and vapour. |
| H302 | Harmful if swallowed. |
| H304 | May be fatal if swallowed and enters airways. |
| H312 | Harmful in contact with skin. |
| H315 | Causes skin irritation. |
| H317 | May cause an allergic skin reaction. |
| H319 | Causes serious eye irritation. |
| H332 | Harmful if inhaled. |
| H335 | May cause respiratory irritation. |
| H336 | May cause drowsiness or dizziness. |
| H373 | May cause damage to organs through prolonged or repeated exposure. |
| H411 | Toxic to aquatic life with long lasting effects. |
| H412 | Harmful to aquatic life with long lasting effects. |

Full text of classifications [SEA/GHS]

| Acute Tox. 4 | ACUTE TOXICITY - Category 4 |
|-------------------|---|
| Aquatic Chronic 2 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2 |
| Aquatic Chronic 3 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3 |
| Asp. Tox. 1 | ASPIRATION HAZARD - Category 1 |
| Eye Irrit. 2 | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2 |
| Flam. Liq. 2 | FLAMMABLE LIQUIDS - Category 2 |
| Flam. Liq. 3 | FLAMMABLE LIQUIDS - Category 3 |
| Skin Irrit. 2 | SKIN CORROSION/IRRITATION - Category 2 |
| Skin Sens. 1 | SKIN SENSITISATION - Category 1 |
| Skin Sens. 1B | SKIN SENSITISATION - Category 1B |
| STOT RE 2 | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2 |
| STOT SE 3 | SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3 |

Date of printing : 29.11.2023

Date of issue/ Date of : 29.11.2023

revision

Date of previous issue : 14.07.2023

Version : 1.01

Contact information of certified author

Responsible Person: Deren Ercan Mail Address: deren.metiner@jotun.com Certificate No: LONCA KDU81/2021.26 Certificate Expiration Date: 14.10.2026

Notice to reader

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 17/18

SECTION 16: Other information

The information in this document is given to the best of Jotun's knowledge, based on laboratory testing and practical experience. Jotun's products are considered as semi-finished goods and as such, products are often used under conditions beyond Jotun's control. Jotun cannot guarantee anything but the quality of the product itself. Minor product variations may be implemented in order to comply with local requirements. Jotun reserves the right to change the given data without further notice.

Users should always consult Jotun for specific guidance on the general suitability of this product for their needs and specific application practices.

If there is any inconsistency between different language issues of this document, the English (United Kingdom) version will prevail.

Date of revision : 29.11.2023 Original preparation date : 14.07.2023 Version : 1.01 18/18